243 related articles for article (PubMed ID: 28656620)
1. Autonomous cortisol secretion in adrenal incidentalomas and increased visceral fat accumulation during follow-up.
Yener S; Baris M; Peker A; Demir O; Ozgen B; Secil M
Clin Endocrinol (Oxf); 2017 Nov; 87(5):425-432. PubMed ID: 28656620
[TBL] [Abstract][Full Text] [Related]
2. Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center.
Patrova J; Kjellman M; Wahrenberg H; Falhammar H
Endocrine; 2017 Nov; 58(2):267-275. PubMed ID: 28887710
[TBL] [Abstract][Full Text] [Related]
3. Visceral fat accumulation and postdexamethasone serum cortisol levels in patients with adrenal incidentaloma.
Debono M; Prema A; Hughes TJ; Bull M; Ross RJ; Newell-Price J
J Clin Endocrinol Metab; 2013 Jun; 98(6):2383-91. PubMed ID: 23633207
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study.
Di Dalmazi G; Vicennati V; Garelli S; Casadio E; Rinaldi E; Giampalma E; Mosconi C; Golfieri R; Paccapelo A; Pagotto U; Pasquali R
Lancet Diabetes Endocrinol; 2014 May; 2(5):396-405. PubMed ID: 24795253
[TBL] [Abstract][Full Text] [Related]
5. Impact of hypercortisolism on skeletal muscle mass and adipose tissue mass in patients with adrenal adenomas.
Delivanis DA; Iñiguez-Ariza NM; Zeb MH; Moynagh MR; Takahashi N; McKenzie TJ; Thomas MA; Gogos C; Young WF; Bancos I; Kyriazopoulou V
Clin Endocrinol (Oxf); 2018 Feb; 88(2):209-216. PubMed ID: 29115003
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Cushing's syndrome in adrenal "incidentalomas": comparison with adrenal Cushing's syndrome.
Reincke M; Nieke J; Krestin GP; Saeger W; Allolio B; Winkelmann W
J Clin Endocrinol Metab; 1992 Sep; 75(3):826-32. PubMed ID: 1517373
[TBL] [Abstract][Full Text] [Related]
7. Clinical features, risk of mass enlargement, and development of endocrine hyperfunction in patients with adrenal incidentalomas: a long-term follow-up study.
Falcetta P; Orsolini F; Benelli E; Agretti P; Vitti P; Di Cosmo C; Tonacchera M
Endocrine; 2021 Jan; 71(1):178-188. PubMed ID: 32915435
[TBL] [Abstract][Full Text] [Related]
8. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features.
Rossi R; Tauchmanova L; Luciano A; Di Martino M; Battista C; Del Viscovo L; Nuzzo V; Lombardi G
J Clin Endocrinol Metab; 2000 Apr; 85(4):1440-8. PubMed ID: 10770179
[TBL] [Abstract][Full Text] [Related]
9. Nonfunctioning adrenal incidentalomas with cortisol post-dexamethasone suppression test >0.9 µg/dL have a higher prevalence of cardiovascular disease than those with values ≤0.9 µg/dL.
Araujo-Castro M; Parra Ramírez P; Martín Rojas-Marcos P; García Centeno R; Gracia Gimeno P; Tomé Fernández-Ladreda M; Sampedro Núñez MA; Higueruela C; Robles Lázaro C
Endocrine; 2023 Feb; 79(2):384-391. PubMed ID: 36261701
[TBL] [Abstract][Full Text] [Related]
10. Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study.
Deutschbein T; Reimondo G; Di Dalmazi G; Bancos I; Patrova J; Vassiliadi DA; Nekić AB; Debono M; Lardo P; Ceccato F; Petramala L; Prete A; Chiodini I; Ivović M; Pazaitou-Panayiotou K; Alexandraki KI; Hanzu FA; Loli P; Yener S; Langton K; Spyroglou A; Kocjan T; Zacharieva S; Valdés N; Ambroziak U; Suzuki M; Detomas M; Puglisi S; Tucci L; Delivanis DA; Margaritopoulos D; Dusek T; Maggio R; Scaroni C; Concistrè A; Ronchi CL; Altieri B; Mosconi C; Diamantopoulos A; Iñiguez-Ariza NM; Vicennati V; Pia A; Kroiss M; Kaltsas G; Chrisoulidou A; Marina LV; Morelli V; Arlt W; Letizia C; Boscaro M; Stigliano A; Kastelan D; Tsagarakis S; Athimulam S; Pagotto U; Maeder U; Falhammar H; Newell-Price J; Terzolo M; Fassnacht M
Lancet Diabetes Endocrinol; 2022 Jul; 10(7):499-508. PubMed ID: 35533704
[TBL] [Abstract][Full Text] [Related]
11. Cardiometabolic profile of non-functioning and autonomous cortisol-secreting adrenal incidentalomas. Is the cardiometabolic risk similar or are there differences?
Araujo-Castro M; Robles Lázaro C; Parra Ramírez P; Cuesta Hernández M; Sampedro Núñez MA; Marazuela M
Endocrine; 2019 Dec; 66(3):650-659. PubMed ID: 31473918
[TBL] [Abstract][Full Text] [Related]
12. Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion.
Androulakis II; Kaltsas GA; Kollias GE; Markou AC; Gouli AK; Thomas DA; Alexandraki KI; Papamichael CM; Hadjidakis DJ; Piaditis GP
J Clin Endocrinol Metab; 2014 Aug; 99(8):2754-62. PubMed ID: 24712565
[TBL] [Abstract][Full Text] [Related]
13. Predictive model for autonomous cortisol secretion development in non-functioning adrenal incidentalomas.
Araujo-Castro M; García Cano AM; Escobar-Morreale HF; Valderrabano P
Hormones (Athens); 2023 Mar; 22(1):51-59. PubMed ID: 36279032
[TBL] [Abstract][Full Text] [Related]
14. Is the 1mg-dexamethasone suppression test a precise marker of glucocorticoid excess and cardiometabolic risk in patients with adrenal incidentalomas?
Araujo-Castro M; Hanzu FA; Pascual-Corrales E; García Cano AM; Marchan M; Escobar-Morreale HF; Valderrabano P; Casals G
Endocrine; 2023 Oct; 82(1):161-170. PubMed ID: 37351760
[TBL] [Abstract][Full Text] [Related]
15. Iliopsoas muscle to visceral fat ratio on CT predicts Cushing's syndrome in elderly females with adrenal tumors.
Uchida T; Yamaguchi H; Arimura Y; Nagayama A; Moritaka K; Inoguchi Y; Ashida K; Nomura M; Nakazato M; Shimoda K
Endocr J; 2023 Aug; 70(8):825-832. PubMed ID: 37258249
[TBL] [Abstract][Full Text] [Related]
16. Pros and cons of dexamethasone suppression test for screening of subclinical Cushing's syndrome in patients with adrenal incidentalomas.
Reimondo G; Allasino B; Bovio S; Saba L; Ardito A; Angeli A; Terzolo M
J Endocrinol Invest; 2011 Jan; 34(1):e1-5. PubMed ID: 20634637
[TBL] [Abstract][Full Text] [Related]
17. Concomitant alterations of metabolic parameters, cardiovascular risk factors and altered cortisol secretion in patients with adrenal incidentalomas during prolonged follow-up.
Papanastasiou L; Alexandraki KI; Androulakis II; Fountoulakis S; Kounadi T; Markou A; Tsiavos V; Samara C; Papaioannou TG; Piaditis G; Kaltsas G
Clin Endocrinol (Oxf); 2017 Apr; 86(4):488-498. PubMed ID: 27992961
[TBL] [Abstract][Full Text] [Related]
18. Attenuation Value in Adrenal Incidentalomas: A Longitudinal Study.
Ceccato F; Tizianel I; Voltan G; Maggetto G; Merante Boschin I; Quaia E; Crimì F; Scaroni C
Front Endocrinol (Lausanne); 2021; 12():794197. PubMed ID: 34925247
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of the dexamethasone suppression test for the prediction of autonomous cortisol secretion-related comorbidities in adrenal incidentalomas.
Araujo-Castro M; Parra Ramírez P; Robles Lázaro C; García Centeno R; Gracia Gimeno P; Fernández-Ladreda MT; Sampedro Núñez MA; Marazuela M; Escobar-Morreale HF; Valderrabano P
Hormones (Athens); 2021 Dec; 20(4):735-744. PubMed ID: 34273083
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of new recommendations for adrenal incidentalomas in the evaluation of excessive cortisol secretion and follow-up.
Ruiz A; Michalopoulou T; Megia A; Näf S; Simón-Muela I; Solano E; Martínez L; Vendrell J
Eur J Clin Invest; 2019 Feb; 49(2):e13048. PubMed ID: 30412278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
